• Publications
  • Influence
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.
RATIONALE Cystic fibrosis is a recessive genetic disease characterized by dehydration of the airway surface liquid and impaired mucociliary clearance. As a result, individuals with the disease haveExpand
  • 883
  • 44
  • PDF
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.
The natural history of cystic fibrosis lung disease is one of chronic progression with intermittent episodes of acute worsening of symptoms frequently called acute pulmonary exacerbations TheseExpand
  • 486
  • 15
  • PDF
Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis
With the improving survival of patients with cystic fibrosis (CF), the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events forExpand
  • 312
  • 14
Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry
Context Cystic fibrosis (CF) is a life-shortening disease, but care has improved. An updated assessment of survival is important for patients and their families and to plan for the health care needsExpand
  • 243
  • 12
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
RATIONALE Patients with cystic fibrosis periodically experience pulmonary exacerbations. Previous studies have noted that some patients' lung function (FEV(1)) does not improve with treatment. Expand
  • 341
  • 11
  • PDF
Review: Staphylococcus aureus and MRSA in cystic fibrosis.
  • C. Goss, M. Muhlebach
  • Medicine
  • Journal of cystic fibrosis : official journal of…
  • 1 September 2011
BACKGROUND Staphylococcus aureus (S. aureus) is one of the earliest bacteria detected in infants and children with cystic fibrosis (CF). The rise of methicillin resistant S. aureus (MRSA) in the lastExpand
  • 169
  • 11
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a
BACKGROUND The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled trials (RCTs)-TRAFFIC and TRANSPORT-in patients with cystic fibrosis whoExpand
  • 136
  • 10
Incidence of acute lung injury in the United States.
OBJECTIVE Recent estimates of acute respiratory distress syndrome (ARDS) incidence have varied from 1.3 to 22 per 100,000 person years (105 person.years); the incidence of acute lung injury (ALI) hasExpand
  • 309
  • 9
Monitoring Influenza Activity in the United States: A Comparison of Traditional Surveillance Systems with Google Flu Trends
Background Google Flu Trends was developed to estimate US influenza-like illness (ILI) rates from internet searches; however ILI does not necessarily correlate with actual influenza virus infections.Expand
  • 137
  • 9
  • PDF
Disease-specific reference equations for lung function in patients with cystic fibrosis.
RATIONALE Forced expiratory volume in one second (FEV1), an important measure of pulmonary disease severity in patients with cystic fibrosis (CF), is frequently expressed as a percentage of aExpand
  • 61
  • 9